Merck Specialties launches campaign to prevent oral cancer

IMT News Desk
IMT News Desk
· 2 min read

Unique mirror-based standee promotes monthly 2-minute oral self-check for early detection of oral cancer

Merck Specialties, a leading pharmaceutical company, launched its national awareness campaign – Two-Minute Action for Oral Cancer Protection – by unveiling a unique mirror-based standee that encourages individuals to spend just two minutes each month checking for early signs of oral cancer using a mirror for self-examination.

The campaign is gaining momentum across India through collaborations with leading oncology hospitals, engagement of medical, surgical, and radiation oncologists, and a multi-channel outreach strategy. It is being amplified through print, digital, and radio platforms and will continue throughout the year as part of a sustained public awareness effort.

Pratima Reddy, MD, Merck Specialties, stated, “We believe that simple tools, when backed by scientific intent and strong communication, can transform preventive care. Our mirror-based standee is designed to engage people at the point of care, providing them with easy-to-understand visual cues and encouraging regular self-examination. Early detection saves lives, and this campaign aims to make that message a reality.”

Dr Sudipto Chatterjee, Country Medical Director, Merck Specialties, added, “This campaign not only educates but also actively involves the public in their health journey. The mirror-on-standee concept combines medical insight with behavioural engagement. We’ve seen excellent responses from both hospitals and the general public, which affirms our belief in community-centred innovation.”

Read Next

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director
News
July 14, 2026

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director

Prime Minister Narendra Modi will dedicate several key healthcare infrastructure projects to the nation on July 17, according to PGIMER Director Dr Vivek Lal. The projects include the Advanced Mother and Child Centre, the Advanced Neurosciences Centre and a new Critical Care Block, all of which are expected to strengthen tertiary care services and expand […]
Article by: IMT News Desk
OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars
News
July 14, 2026

OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars

OneSource Specialty Pharma Limited and Formycon AG have announced a strategic manufacturing partnership for biosimilars, bringing together Formycon’s biosimilar development expertise and OneSource’s integrated biologics manufacturing capabilities to support global markets. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon and provide both drug substance and drug product manufacturing from its […]
Article by: IMT News Desk
FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi
News
July 14, 2026

FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi

The U.S. Food and Drug Administration has approved an at-home starting dose of Eisai and Biogen’s Alzheimer’s drug Leqembi, allowing some patients to begin treatment with injections administered by themselves or a caregiver. The decision expands access to the drug’s subcutaneous formulation, which can now be used as a starter dose rather than only after […]
Article by: IMT News Desk
Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition
News
July 14, 2026

Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition

Emcure Pharmaceuticals Limited has announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited, alongside a leadership transition, as it sharpens its focus on biologics and biosimilars. The company is acquiring the entire 12.05% minority stake in Gennova held by Dr Sanjay Singh and others, taking its ownership to 100% and making Gennova […]
Article by: IMT News Desk